Sarepta Therapeutics (LTS:0L35) Institutional Ownership: 58.16% (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0L35 Sarepta Therapeutics Inc LTS:0L35
50 GF Score
Price $15.39
GF Value $125.20
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Institutional Ownership?

Sarepta Therapeutics LTS:0L35 +1.39% 50 Institutional Ownership is 58.16% as of Aug. 04, 2026. GuruFocus rates LTS:0L35 with a GF Score™ of 50/100 and a GF Value™ of $125.20 (Possible Value Trap). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sarepta Therapeutics's institutional ownership is 58.16%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sarepta Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sarepta Therapeutics's Float Percentage Of Total Shares Outstanding is 83.42%.

Sarepta Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Sarepta Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics Institutional Ownership Chart

Sarepta Therapeutics Historical Data

The historical data trend for Sarepta Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 42.86 42.80 43.13 45.15 47.28 48.07 50.02 50.28 50.62 58.16
LTS:0L35
50GF Score
Sarepta Therapeutics Inc LTS:0L35
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sarepta Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 58.16% mean?
Sarepta Therapeutics (LTS:0L35) has a Institutional Ownership of 58.16% as of Aug. 04, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Institutional Ownership too high?
Sarepta Therapeutics' current Institutional Ownership is 58.16%. Overall, Sarepta Therapeutics has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Institutional Ownership compare to MPLT and ZYME?
Sarepta Therapeutics' Institutional Ownership of 58.16% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Institutional Ownership is 58.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (LTS:0L35) is currently considered Possible Value Trap. The stock's GF Value™ is $125.20, compared to a current price of $15.39 — trading 87.7% below its estimated fair value. The current Institutional Ownership is 58.16%. Sarepta Therapeutics' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Sarepta Therapeutics (LTS:0L35), the current Institutional Ownership is 58.16% as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (LTS:0L35) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of $15.39 is trading 87.7% below its estimated GF Value™ of $125.20. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0L35:

  • Institutional Ownership: 58.16%
  • GF Value™: $125.20 vs. price of $15.39 (87.7% below fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the LTS:0L35 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
50GF Score

Get the complete analysis for LTS:0L35

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.39
Price
$125.20
GF Value